Biogen (BSP:BIIB34) Total Stockholders Equity : R$90,592 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Biogen Total Stockholders Equity?

Biogen's Total Stockholders Equity for the quarter that ended in Sep. 2024 was R$90,592 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Biogen's Book Value per Share for the quarter that ended in Sep. 2024 was R$103.21. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Biogen's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.41.

Biogen Total Stockholders Equity Historical Data

The historical data trend for Biogen's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Total Stockholders Equity Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

54,767.16

55,049.83

61,616.92

70,277.35

72,514.10

Biogen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Stockholders Equity	Get a 7-Day Free Trial															71,531.14	72,514.10	75,757.70	85,580.28	90,592.32

Biogen (BSP:BIIB34) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Biogen's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(90592.316	-	0)	/	877.711
	=	103.21

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Biogen's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9680.628	+	27150.726)	/	90592.316
	=	0.41

Biogen Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Biogen's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy 0R1B:UK IDP:Germany IDP:Germany IDP:Germany IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Headlines

No Headlines